TRANCYP Tablet is a potent antidepressant formulation developed by BluepillExpress containing Tranylcypromine, a non-hydrazine monoamine oxidase inhibitor (MAOI) known for its effectiveness in treatment-resistant depression, atypical depression, and major depressive episodes that have not responded to first-line therapies such as SSRIs or SNRIs.

As a third-party manufacturer of global pharmaceutical standards, BluepillExpress ensures that every TRANCYP Tablet is manufactured in compliance with WHO-GMP, ISO, and Schedule M guidelines. The facility utilizes state-of-the-art technology to perform precision blending, compression, and coating, ensuring each tablet meets rigorous pharmaceutical-grade purity, stability, and bioavailability requirements.

Pharmacologically, Tranylcypromine works by irreversibly inhibiting the activity of monoamine oxidase enzymes (MAO-A and MAO-B), which are responsible for the breakdown of key neurotransmitters such as serotonin, norepinephrine, and dopamine. By preventing their breakdown, TRANCYP increases the availability of these mood-elevating chemicals in the brain, thereby alleviating symptoms of deep-seated and chronic depression.

Indications for TRANCYP Tablet include:

Major Depressive Disorder (MDD)

Atypical depression with features like hypersomnia and increased appetite

Depression with suicidal ideation, especially when refractory to other treatments

Persistent mood disorders unresponsive to SSRIs, tricyclics, or SNRIs

One of the key strengths of TRANCYP is its ability to bring therapeutic relief in patients who have failed to benefit from two or more classes of antidepressants. It is often prescribed by psychiatrists in specialized settings, with careful dietary and pharmacologic supervision to mitigate potential interactions.

TRANCYP is best administered once or twice daily, depending on clinical assessment. Patients on this medication require dietary restrictions to avoid tyramine-containing foods such as aged cheeses, fermented products, and certain wines, due to the risk of hypertensive crisis. BluepillExpress includes all safety and dosage guidelines in its packaging and patient inserts to ensure informed use.

Though highly effective, TRANCYP must be initiated and discontinued cautiously. Washout periods are mandatory when switching from or to other antidepressant classes. Clinical monitoring is advised for the first few weeks to observe for improvements in mood and to watch for side effects such as insomnia, dizziness, dry mouth, or hypertensive responses.

Each batch of TRANCYP Tablet is:

Subjected to validated HPLC testing for active ingredient quantification

Evaluated for dissolution rate, hardness, friability, and disintegration

Quality-checked for microbial contamination, uniformity of content, and packaging integrity

Export-compliant and accompanied by a Certificate of Analysis (COA) and all necessary regulatory documentation

BluepillExpress also offers customized packaging and labeling for international clients, making TRANCYP a widely accepted export product in regulated markets across Asia, Africa, Latin America, and Eastern Europe.

TRANCYP is presented in moisture-resistant aluminum blister strips or HDPE bottles with tamper-proof seals to preserve its potency and shelf life. BluepillExpress upholds a commitment to clinical safety and therapeutic efficacy, making TRANCYP a reliable choice in the psychiatric healthcare domain.

In today’s mental health landscape, where resistant depression is increasingly diagnosed, TRANCYP from BluepillExpress fills a critical therapeutic gap—offering hope, relief, and recovery to patients who have struggled for far too long.